Alpha Teknova, Inc. Common Stock earnings per share and revenue
On Nov 06, 2025, TKNO reported earnings of -0.08 USD per share (EPS) for Q3 25, beating the estimate of -0.09 USD, resulting in a 16.58% surprise. Revenue reached 10.45 million, compared to an expected 10.48 million, with a -0.25% difference. The market reacted with a -2.08% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analysts forecast an EPS of -0.09 USD, with revenue projected to reach 9.91 million USD, implying an increase of 12.50% EPS, and decrease of -5.20% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
What were Alpha Teknova, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Alpha Teknova, Inc. Common Stock reported EPS of -$0.08, beating estimates by 16.58%, and revenue of $10.45M, -0.25% below expectations.
How did the market react to Alpha Teknova, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -2.08%, changed from $4.81 before the earnings release to $4.71 the day after.
When is Alpha Teknova, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 25, 2026.
What are the forecasts for Alpha Teknova, Inc. Common Stock's next earnings report?
Based on 7
analysts, Alpha Teknova, Inc. Common Stock is expected to report EPS of -$0.09 and revenue of $9.91M for Q4 2025.